申请人:Abbott GmbH & Co. KG
公开号:US07049312B1
公开(公告)日:2006-05-23
Q is —N=or CR2
X is S, O or NOR3
Y is —O—, —S—, —SO— or —SO2—
R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group
R2 is H or a substituent
R3 is H, or —C(O)R4
R4 is a substituted or unsubstituted aliphatic or aromatic group
n is an integer from 0 to 1
Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.
Q是-N=或CR2 X是S,O或NOR3 Y是-O-,-S-,-SO-或-SO2-R和R1分别是H,一个取代或未取代的脂肪族,芳香族,杂环芳香族或芳基烃基团R2是H或一个取代基R3是H,或-C(O)R4 R4是一个取代或未取代的脂肪族或芳香族团n是从0到1的整数具有结构式I和其生理上可接受的盐的化合物,是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种酪氨酸激酶参与血管生成过程。因此,这些化合物可以改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症和过度增殖性疾病。